% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Gillessen:275214,
author = {S. Gillessen and A. Bossi and I. D. Davis and J. de Bono
and K. Fizazi and N. D. James and N. Mottet and N. Shore and
E. Small and M. Smith and C. J. Sweeney and B. Tombal and E.
S. Antonarakis and A. M. Aparicio and A. J. Armstrong and G.
Attard and T. M. Beer and H. Beltran and A. Bjartell and P.
Blanchard and A. Briganti and R. G. Bristow and M. Bulbul
and O. Caffo and D. Castellano and E. Castro and H. H. Cheng
and K. N. Chi and S. Chowdhury and C. S. Clarke and N.
Clarke and G. Daugaard and M. De Santis and I. Duran and R.
Eeles and E. Efstathiou and J. Efstathiou and O. N. Ekeke
and C. P. Evans and S. Fanti and F. Y. Feng and V. Fonteyne
and N. Fossati and M. Frydenberg and D. George and M. Gleave
and G. Gravis and S. Halabi and D. Heinrich and K.
Herrmann$^*$ and C. Higano and M. S. Hofman and L. G.
Horvath and M. Hussain and B. A. Jereczek-Fossa and R. Jones
and R. Kanesvaran and P.-L. Kellokumpu-Lehtinen and R. B.
Khauli and L. Klotz and G. Kramer and R. Leibowitz and C.
Logothetis and B. Mahal and F. Maluf and J. Mateo and D.
Matheson and N. Mehra and A. Merseburger and A. K. Morgans
and M. J. Morris and H. Mrabti and D. Mukherji and D. G.
Murphy and V. Murthy and P. L. Nguyen and W. K. Oh and P.
Ost and J. M. O'Sullivan and A. R. Padhani and C. J. Pezaro
and D. M. C. Poon and C. C. Pritchard and D. M. Rabah and D.
Rathkopf and R. E. Reiter and M. A. Rubin and C. J. Ryan and
F. Saad and J. P. Sade and O. Sartor and H. I. Scher and N.
Sharifi and I. Skoneczna and H. Soule and D. E. Spratt and
S. Srinivas and C. N. Sternberg and T. Steuber and H. Suzuki
and M. R. Sydes and M.-E. Taplin and D. Tilki and L.
Türkeri and F. Turco and H. Uemura and H. Uemura and Y.
Ürün and C. L. Vale and I. van Oort and N. Vapiwala and J.
Walz and K. Yamoah and D. Ye and E. Y. Yu and A. Zapatero
and T. Zilli and A. Omlin},
title = {{M}anagement of patients with advanced prostate
cancer-metastatic and/or castration-resistant prostate
cancer: report of the {A}dvanced {P}rostate {C}ancer
{C}onsensus {C}onference ({APCCC}) 2022.},
journal = {European journal of cancer},
volume = {185},
issn = {0014-2964},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2023-00672},
pages = {178 - 215},
year = {2023},
abstract = {Innovations in imaging and molecular characterisation
together with novel treatment options have improved outcomes
in advanced prostate cancer. However, we still lack
high-level evidence in many areas relevant to making
management decisions in daily clinical practise. The 2022
Advanced Prostate Cancer Consensus Conference (APCCC 2022)
addressed some questions in these areas to supplement
guidelines that mostly are based on level 1 evidence.To
present the voting results of the APCCC 2022.The experts
voted on controversial questions where high-level evidence
is mostly lacking: locally advanced prostate cancer;
biochemical recurrence after local treatment; metastatic
hormone-sensitive, non-metastatic, and metastatic
castration-resistant prostate cancer; oligometastatic
prostate cancer; and managing side effects of hormonal
therapy. A panel of 105 international prostate cancer
experts voted on the consensus questions.The panel voted on
198 pre-defined questions, which were developed by 117
voting and non-voting panel members prior to the conference
following a modified Delphi process. A total of 116
questions on metastatic and/or castration-resistant prostate
cancer are discussed in this manuscript. In 2022, the voting
was done by a web-based survey because of COVID-19
restrictions.The voting reflects the expert opinion of these
panellists and did not incorporate a standard literature
review or formal meta-analysis. The answer options for the
consensus questions received varying degrees of support from
panellists, as reflected in this article and the detailed
voting results are reported in the supplementary material.
We report here on topics in metastatic, hormone-sensitive
prostate cancer (mHSPC), non-metastatic,
castration-resistant prostate cancer (nmCRPC), metastatic
castration-resistant prostate cancer (mCRPC), and
oligometastatic and oligoprogressive prostate cancer.These
voting results in four specific areas from a panel of
experts in advanced prostate cancer can help clinicians and
patients navigate controversial areas of management for
which high-level evidence is scant or conflicting and can
help research funders and policy makers identify information
gaps and consider what areas to explore further. However,
diagnostic and treatment decisions always have to be
individualised based on patient characteristics, including
the extent and location of disease, prior treatment(s),
co-morbidities, patient preferences, and treatment
recommendations and should also incorporate current and
emerging clinical evidence and logistic and economic
factors. Enrolment in clinical trials is strongly
encouraged. Importantly, APCCC 2022 once again identified
important gaps where there is non-consensus and that merit
evaluation in specifically designed trials.The Advanced
Prostate Cancer Consensus Conference (APCCC) provides a
forum to discuss and debate current diagnostic and treatment
options for patients with advanced prostate cancer. The
conference aims to share the knowledge of international
experts in prostate cancer with healthcare providers
worldwide. At each APCCC, an expert panel votes on
pre-defined questions that target the most clinically
relevant areas of advanced prostate cancer treatment for
which there are gaps in knowledge. The results of the voting
provide a practical guide to help clinicians discuss
therapeutic options with patients and their relatives as
part of shared and multidisciplinary decision-making. This
report focuses on the advanced setting, covering metastatic
hormone-sensitive prostate cancer and both non-metastatic
and metastatic castration-resistant prostate cancer.Report
of the results of APCCC 2022 for the following topics:
mHSPC, nmCRPC, mCRPC, and oligometastatic prostate cancer.At
APCCC 2022, clinically important questions in the management
of advanced prostate cancer management were identified and
discussed, and experts voted on pre-defined consensus
questions. The report of the results for metastatic and/or
castration-resistant prostate cancer is summarised here.},
keywords = {Androgen receptor pathway inhibitors (ARPI) (Other) /
Chemotherapy (Other) / Hormonal treatment (Other) /
Metastatic castration-resistant prostate cancer (mCRPC) and
oligometastatic and oligoprogressive prostate cancer (Other)
/ Metastatic hormone-sensitive prostate cancer (mHSPC)
(Other) / Next-generation imaging (Other) / Non metastatic
castration-resistant prostate cancer (nmCRPC) (Other) / PSMA
PET-imaging (Other) / Systemic therapy (Other)},
cin = {ED01},
ddc = {610},
cid = {I:(DE-He78)ED01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37003085},
doi = {10.1016/j.ejca.2023.02.018},
url = {https://inrepo02.dkfz.de/record/275214},
}
guest ::